Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Single-Arm Multi-Center Trial Evaluating the Efficacy of Pembrolizumab in the Treatment of Subjects With Incurable Platinum-Refractory Germ Cell Tumors: Hoosier Cancer Research Network GU14-206

NCT02499952 is registered in ClinicalTrials.gov with Nasser Hanna, M.D. as lead sponsor.

NCT NCT02499952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02499952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Single-Arm Multi-Center Trial Evaluating the Efficacy of Pembrolizumab in the Treatment of Subjects With Incurable Platinum-Refractory Germ Cell Tumors: Hoosier Cancer Research Network GU14-206
Lead sponsor
Nasser Hanna, M.D.
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2016
Completion date
January 13, 2017
Enrollment
12 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

genital neoplasms, female, genital neoplasms, male, germ cell neoplasms, mediastinal neoplasms, non seminomatous germ cell tumors, ovarian neoplasms, testicular neoplasms